# GE HealthCare account plan

> GE HealthCare sells imaging, ultrasound, monitoring and contrast agents in over 160 countries: $20,625 million FY2025 revenue, ~54,000 colleagues.

## At a glance

GE HealthCare Technologies Inc. (Nasdaq: GEHC), headquartered in Chicago and spun off from General Electric on January 3, 2023, sells medical devices, consumables, services and AI-enabled cloud and software to hospitals, health systems and researchers in over 160 countries. Its portfolio spans CT, MR, molecular imaging, X-ray, ultrasound and interventional systems, patient monitoring and anesthesia, and contrast media and radiopharmaceuticals. FY2025 total revenues were $20,625 million (+4.8% reported, +3.5% organic), with operating income of $2,763 million, net income attributable of $2,084 million and free cash flow of $1,505 million. It has approximately 54,000 colleagues, including about 9,700 sales professionals and 8,900 field service engineers, and manufactures in 44 facilities across 17 countries.

## Business units

- **Advanced Imaging Solutions (AIS)** (about 71% of Q2 2026 revenue ($3,771 million)): Formed in Q2 2026 by combining Imaging and Advanced Visualization Solutions; it covers Radiology (CT, MR, molecular imaging, X-ray, women's health), Procedural Guidance and Specialized Ultrasound, and includes Intelerad imaging software. Q2 2026 revenue rose 7.9% (+5.0% organic) with segment EBIT of $525 million (13.9% margin). In FY2025 Imaging was led by Roland Rott and AVS by Philip Rackliffe.
- **Pharmaceutical Diagnostics (PDx)** (about 14% of FY2025 revenue ($2,900 million)): Contrast media for CT, X-ray, MR and ultrasound and radiopharmaceuticals for SPECT and PET in neurology, cardiology and oncology; it is the highest-margin segment. Q2 2026 revenue was $843 million (+14.6% organic) with a 29.6% EBIT margin, helped by volume and price. Led by Kevin O'Neill.
- **Patient Care Solutions (PCS)** (about 15% of FY2025 revenue ($3,086 million)): Patient monitoring, diagnostic cardiology, maternal infant care and anesthesia delivery, plus consumables and vendor-agnostic digital solutions. Q2 2026 revenue fell 13.3% to $675 million with segment EBIT of $(26) million on supply and fulfillment issues, and the business is under a review of strategic options. Led by Jeannette Bankes since May 2025.

## Strategic priorities

- **D3 growth strategy**: Growth is framed as D3, combining smart devices and drugs, a disease-state focus and digital capabilities, particularly AI, executed through the Heartbeat lean business system.
- **New product cycle**: New products such as Photonova Spectra photon-counting CT (shipments from early 2027), Total Body PET, SIGNA Bolt 3T MR and Vivid Pioneer ultrasound are meant to lift growth from the 3%-4% lane to mid-single digits; they are still under 20% of order value.
- **Grow Pharmaceutical Diagnostics**: Management says PDx is in "a renaissance window"; the target for the Flyrcado PET tracer is $500 million or more in annual revenue by 2028, and the contrast market is expected to double over the next decade.
- **Medium-term margin and growth targets**: Medium-term targets are mid-single-digit organic growth, a high-teens to 20% adjusted EBIT margin and 90% free cash flow conversion; the CEO says the 17-20 margin range remains on track.
- **Fix and review Patient Care Solutions**: The first job is to get PCS supply and fulfillment back on track, then decide on options including continued ownership or a sale, with an update expected around February.
- **Stabilise China**: China is still modeled down in 2026; the company has localised most in-China-for-China manufacturing, with another 10% to go, and set up a provincial government affairs group to address volume-based procurement.

## Latest results

In Q2 2026 total revenues were $5,295 million, up 5.7% reported and 3.5% organic, led by PDx and AIS while PCS fell 13.3%. Organic orders grew 11.1%, book-to-bill was 1.15 times and backlog reached a record $23.9 billion. Adjusted EBIT was $750 million (14.2% margin, down 40 bps) as PCS and inflation in memory chips, oil and freight weighed; Adjusted EPS was $1.13 vs $1.06. IEEPA tariff refunds of $107 million were received in the quarter. Guidance for 2026 was reaffirmed: organic growth of 3.0% to 4.0%, Adjusted EBIT margin of 15.4% to 15.7%, Adjusted EPS of $4.80 to $5.00 and free cash flow of approximately $1.6 billion.

## Investments and deals

- **Intelerad acquisition**: Acquired March 18, 2026 for approximately $2,293 million in cash; a cloud-first medical imaging software and workflow company with a significant outpatient presence, now part of AIS.
- **Nihon Medi-Physics**: The remaining 50% of the Japanese radiopharmaceutical manufacturer was bought for $271 million, making it wholly owned on March 31, 2025.
- **AI imaging tuck-ins**: icometrix (AI brain imaging) was acquired for approximately $98 million plus up to $35 million earn-out in November 2025, alongside Spectronic Medical AB.
- **R&D and capacity capex**: FY2025 R&D spending was $1,260 million and capex $482 million; capital priorities remain organic investment first, then tuck-in M&A, then buybacks.

## Challenges and risks

- **Tariffs and cost inflation**: Tariffs cut operating income by approximately $245 million in 2025, and 2026 guidance absorbs approximately $250 million of inflation from memory chips, oil and freight linked partly to the Middle East conflict.
- **Patient Care Solutions operations**: PCS revenue fell 13.5% organically in Q2 2026 with negative EBIT, driven by supply of critical components, end-of-life components and fulfillment problems.
- **China competition and procurement**: China region revenue fell 4.6% in FY2025 amid local competition and volume-based procurement, which the company models will ultimately be over half of the market.
- **Supply chain inputs**: The business depends on helium, iodine and rare earth minerals, and China tightened rare-earth export controls in 2025.
- **Debt and pension load**: Total debt was $10,093 million at June 30, 2026, and pension plans carry a total funded deficit of $4,365 million.

## What leadership says

> "We delivered record orders and backlog in the second quarter, with orders growth across every segment, demonstrating strong commercial execution, including the adoption of new products." — Peter Arduini, President and CEO, GE HealthCare second quarter 2026 earnings release, 2026-07-29

> "while we are focused on returning the business to growth and profitability, we are reviewing strategic options to maximize its long-term value." — Peter Arduini, President and CEO, On Patient Care Solutions, Q2 2026 earnings release, 2026-07-29

> "this is the best lineup GE HealthCare has ever had, period." — Peter Arduini, President and CEO, On vascular products, Wells Fargo 21st Annual Healthcare Conference, 2026-09-09

> "we're increasingly confident in the $500 million+ by 2028." — Jay Saccaro, then VP and CFO, On Flyrcado, Jefferies Global Healthcare Conference, 2026-06-03


## Where a supplier can help

- **Component supply and manufacturing for PCS**: Tied to the Patient Care Solutions challenge: suppliers of critical electronic components, redesign of end-of-life parts or contract manufacturing can address the supply and fulfillment issues behind the decline.
- **Logistics and input-cost mitigation**: Tied to the tariffs and inflation challenge: freight optimisation, alternative sourcing of memory chips and rare earths, and trade-compliance services fit an inflation load of approximately $250 million.
- **Radiopharmacy delivery and workflow**: Tied to the PDx growth priority: Flyrcado adoption depends on radiopharmacy delivery reliability and clinic workflow, so specialised logistics and scheduling tools are relevant.
- **Software and AI integration**: Tied to the D3 strategy and the Intelerad acquisition: cloud infrastructure, data integration and AI tooling partners can support imaging software and internal productivity work with agents.
- **Local sourcing in China**: Tied to the China priority: local suppliers and manufacturing partners can help complete the remaining localisation needed to compete under volume-based procurement.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Form 10-K for fiscal year 2025](https://www.sec.gov/Archives/edgar/data/1932393/000193239326000007/gehc-20251231.htm)

Annual report · 2026-02-04

- GE HealthCare Technologies Inc. (Chicago; Nasdaq: GEHC), spun off from General Electric on January 3, 2023, sells medical devices, consumables, services and AI-enabled cloud and software to hospitals, health systems and researchers in over 160 countries, with approximately 54,000 colleagues, 9,700 sales professionals and 8,900 field service engineers.
- FY2025 total revenues $20,625 million, up 4.8% reported and 3.5% organic; products $13,661 million, services $6,964 million. Operating income $2,763 million; net income attributable $2,084 million; Adjusted EBIT $3,155 million (15.3% margin, down 100 bps); diluted EPS $4.55, Adjusted EPS $4.59; free cash flow $1,505 million.
- Four segments in FY2025: Imaging ($9,245 million, segment EBIT margin 9.6%), Advanced Visualization Solutions ($5,354 million, 22.0%), Patient Care Solutions ($3,086 million, 6.8%, revenue down 1.2%) and Pharmaceutical Diagnostics ($2,900 million, 30.1%, up 15.6%).
- Regions: USCAN $9,531 million (+6.1%), EMEA $5,425 million (+7.4%), China region $2,251 million (-4.6%), Rest of World $3,418 million (+4.2%). China faces local competition and Volume Based Procurement.
- Tariffs cut operating income by approximately $245 million and cash flows by approximately $285 million in 2025; mitigation is not expected to offset them fully.
- Remaining performance obligations $15,729 million at year-end (services $10,728 million); contract liabilities $2,899 million.
- M&A: remaining 50% of Nihon Medi-Physics (radiopharmaceuticals, Japan) bought for $271 million; icometrix (AI brain imaging) for approximately $98 million plus up to $35 million earn-out; agreement to buy Intelerad (imaging software, outpatient) for $2,300 million in cash.
- Balance sheet: total debt $10,003 million, $2,750 million of new notes issued in 2025; $1,000 million buyback authorized April 2025 ($200 million used); quarterly dividend $0.035.
- Competitors named: Siemens Healthineers, Philips Healthcare, United Imaging, Mindray and Canon; in PDx Bayer, Bracco, Guerbet and Curium.
- Main risks: competition, tariffs and geopolitics, payer cost control (including China's volume-based procurement), execution of AI/cloud strategy, supply chain (helium, iodine, rare earths), regulation, $10,003 million of debt and large pension liabilities.

### [Form 10-Q for the quarter ended June 30, 2026](https://www.sec.gov/Archives/edgar/data/1932393/000193239326000046/gehc-20260630.htm)

Interim report · 2026-07-29

- Q2 2026 total revenues $5,295 million, up 5.7% reported and 3.5% organic; H1 2026 $10,425 million, up 6.6% (organic 3.2%).
- New segment structure from Q2 2026: Imaging and AVS combined into Advanced Imaging Solutions (AIS) to give three reportable segments, AIS, PDx and PCS; history recast.
- AIS Q2 revenue $3,771 million (+7.9%, organic +5.0%), segment EBIT $525 million (13.9%); Radiology $2,388 million, Procedural Guidance $715 million, Specialized Ultrasound $668 million.
- PDx Q2 revenue $843 million (+15.6%, organic +14.6%), EBIT $250 million (29.6%), on volume and price in contrast media and radiopharmaceuticals.
- PCS Q2 revenue $675 million (-13.3%), segment EBIT $(26) million, because of operational and fulfillment challenges.
- Q2 operating income $739 million; net income attributable $561 million; Adjusted EBIT $750 million (14.2%); Adjusted EPS $1.13 vs $1.06. H1 free cash flow $180 million vs $106 million.
- Intelerad acquired March 18, 2026 for approximately $2,293 million in cash, included in AIS.
- IEEPA tariff refunds: $107 million received and a $38 million receivable; pre-tax benefits of $106 million (2025 tariffs) and $23 million (2026 tariffs) in Q2. Tariffs still cut Q2 operating income by $68 million before refunds.
- RPO $16,118 million at June 30, 2026; total debt $10,093 million; cash $2,105 million; $300 million of buybacks in H1.
- Middle East conflict, memory chips, freight and oil-linked costs raised costs in Q2; China competition and volume-based procurement remain watch points.

### [GE HealthCare reports second quarter 2026 financial results (earnings release)](https://www.sec.gov/Archives/edgar/data/1932393/000193239326000045/release2q26earnings.htm)

Report · 2026-07-29

- Q2 2026 revenue $5.3 billion, +5.7% reported, organic +3.5%, led by PDx and AIS; PCS "continued to be challenged".
- Record organic orders growth of 11.1% (vs 3.4% a year earlier), book-to-bill 1.15 times, backlog $23.9 billion.
- Adjusted EBIT margin 14.2% (down 40 bps) hurt by PCS and inflation in memory chips, oil and freight; diluted EPS $1.24 (+16.5%), Adjusted EPS $1.13 (+6.6%).
- Segment EBIT margins: AIS 13.9% (+90 bps), PDx 29.6% (+30 bps), PCS (3.8)% (down 1,150 bps).
- CEO Peter Arduini: PCS is under a review of strategic options "to maximize its long-term value".
- 2026 guidance reaffirmed: organic growth 3.0% to 4.0%, Adjusted EBIT margin 15.4% to 15.7%, Adjusted EPS $4.80 to $5.00, free cash flow approximately $1.6 billion; approximately $250 million of inflation from memory chips, oil and freight assumed.
- Q2 buyback of 3.3 million shares for $200 million; $500 million left in the authorization; dividend $0.035 per share.
- Commercial highlights: Catholic Health partnership on Long Island, theranostics collaborations with Mayo Clinic and University Hospital Essen, FDA clearance for MIM Contour ProtégéAI+ 2.0.

### [GE HealthCare Q2 2026 earnings call transcript](https://www.fool.com/earnings/call-transcripts/2026/08/03/ge-healthcare-gehc-q2-2026-earnings-call-transcript/)

Executive talk · Peter Arduini, President and CEO · 2026-07-29

- Peter Arduini (CEO) called Q2 2026 orders (+11%), backlog growth ($2.6 billion year on year) and book-to-bill (1.15x) record levels, with demand healthy in all 3 segments and no one-time items; about 6 enterprise accounts contributed.
- Strategy: D3 (smart devices and drugs, a disease-state focus, digital/AI) plus the Heartbeat lean business system; "AI inside" to grow with lower G&A.
- PCS: revenue -13.5% organic and negative EBIT on supply and fulfillment issues; a review of options "including continued ownership, a sale and other value-enhancing transactions" is under way.
- PDx: organic +14.6%, EBIT margin 29.6%; Flyrcado reached 545 doses in the week ending July 24 (about 40% above April); target of $500 million or more annual revenue by 2028 reaffirmed; contrast demand "close to outpacing total market supply".
- New products: Photonova Spectra photon-counting CT (CE marking expected H2 2026), Vivid Pioneer ultrasound with higher gross margin, SIGNA Bolt 3T MR; new products are still under 20% of order value.
- Catholic Health (New York) signed an approximately $500 million agreement for equipment, service and process expertise.
- Guidance kept: 3% to 4% organic growth, 15.4% to 15.7% Adjusted EBIT margin, Adjusted EPS $4.80 to $5; medium-term targets reaffirmed.
- CFO Jay Saccaro is leaving; George Newcomb is interim CFO. China: still assumes a year-over-year decline in 2026.

### [Wells Fargo 21st Annual Healthcare Conference fireside chat](https://stockanalysis.com/stocks/gehc/transcripts/740200-wells-fargo-21st-annual-healthcare-conference/)

Executive talk · Peter Arduini, President and CEO · 2026-09-09

- Peter Arduini (CEO) at the Wells Fargo Healthcare Conference, September 9, 2026, with interim CFO George Newcomb.
- Q2 orders growth over 11% was all equipment; hospitals show no pullback in capital spending; nearly 80% of Q3 revenue was committed entering the quarter.
- PCS review: first fix the business (supply, end-of-life components), then decide whether all parts belong together or "better someplace else"; an update is expected around February.
- China is stabilizing but still expected slightly down in 2026; VBP may exceed half of the market; local sourcing is key.
- PDx is in "a renaissance window"; contrast demand and supply "just matching up"; LRP of high single-digit growth is being outperformed. Flyrcado $500 million in 2028 target reaffirmed.
- Photonova Spectra has CE mark and 510(k); shipments ramp from early 2027. MR SIGNA Bolt is "picking up share for the first time in quite some time"; "this is the best lineup GE HealthCare has ever had" in vascular.
- Medium-term 17-20% margin target is still on track despite almost a couple of hundred basis points of headwinds; new CFO Bill Grogan joins the following week.
- Capital allocation: internal investment first, tuck-in M&A like Intelerad (growing high single digits, margins in the 30s), selective buybacks.

### [Jefferies Global Healthcare Conference 2026 fireside chat](https://stockanalysis.com/stocks/gehc/transcripts/656478-jefferies-global-healthcare-conference-2026/)

Executive talk · James (Jay) Saccaro, Vice President and Chief Financial Officer · 2026-06-03

- Jay Saccaro (then VP and CFO) at the Jefferies Global Healthcare Conference, June 3, 2026.
- Q1 2026: two-year orders growth of 11%, book-to-bill 1.07x, record backlog of $21.8 billion, revenue +2.9%, mostly from existing products.
- Guidance was cut because of about $250 million of inflation (Middle East conflict about $150 million for logistics and rare earths, plus memory chips); a $0.15 reduction at both ends of the range, with buffers built in.
- Price lags cost because orders in the book carry price risk; much larger price impact expected next year.
- New products (photon-counting CT, Total Body PET, next-gen SPECT, MR with Freelium, Vivid Pioneer, Allia Moveo) are meant to lift growth from the 3%-4% lane to mid-single digits; photon-counting pipeline over $100 million.
- Tariffs: about $250 million net impact last year ($500 million gross before mitigation).
- Flyrcado: $25 million run rate in Q1, $50 million annual run rate in Q2, customer base up 50% since the start of the year; confidence in $500 million+ by 2028.
- China modeled down in 2026 under new leader Will Song; capital allocation favours R&D, then deals where GE HealthCare is one of one or two buyers (Intelerad), and buybacks ($100 million at $70 in Q1).

## Questions about GE HealthCare

### What does GE HealthCare do?

GE HealthCare sells medical imaging and ultrasound systems, patient monitoring and anesthesia equipment, contrast media and radiopharmaceuticals, services and AI-enabled software to hospitals, health systems and researchers in over 160 countries.

### What is GE HealthCare's revenue?

Total revenues were $20,625 million in FY2025, up 4.8% reported. Q2 2026 revenues were $5,295 million, up 5.7%.

### How many employees does GE HealthCare have?

Approximately 54,000 colleagues, including about 9,700 sales professionals and 8,900 field service engineers.

### Who leads GE HealthCare?

Peter Arduini has been President and CEO since the spin-off. CFO Jay Saccaro left in 2026; George Newcomb served as interim CFO and new CFO Bill Grogan was due to join in mid-September 2026.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
